Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 2 von 975
Pharmaceutical research, 2006-06, Vol.23 (6), p.1089-1116
2006
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
CYP induction-mediated drug interactions: in vitro assessment and clinical implications
Ist Teil von
  • Pharmaceutical research, 2006-06, Vol.23 (6), p.1089-1116
Ort / Verlag
United States: Springer Nature B.V
Erscheinungsjahr
2006
Quelle
springer (창간호~2014)
Beschreibungen/Notizen
  • Cytochrome P450 (CYP) induction-mediated interaction is one of the major concerns in clinical practice and for the pharmaceutical industry. There are two major issues associated with CYP induction: a reduction in therapeutic efficacy of comedications and an induction in reactive metabolite-induced toxicity. Because CYP induction is a metabolic liability in drug therapy, it is highly desirable to develop new drug candidates that are not potent CYP inducer to avoid the potential of CYP induction-mediated drug interactions. For this reason, today, many drug companies routinely include the assessment of CYP induction at the stage of drug discovery as part of the selection processes of new drug candidates for further clinical development. The purpose of this article is to review the molecular mechanisms of CYP induction and the clinical implications, including pharmacokinetic and pharmacodynamic consequences. In addition, factors that affect the degree of CYP induction and extrapolation of in vitro CYP induction data to in vivo situations will also be discussed. Finally, assessment of the potential of CYP induction at the drug discovery and development stage will be discussed.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX